Navigation Links
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
Date:2/1/2010

an AV fistula or AV graft for hemodialysis. Results showed that Vascugel was well tolerated, with no difference in early complication rates between the Vascugel and placebo groups at four weeks (10.9 percent vs. 21.1 percent, respectively). Results also demonstrated a trend for improved primary patency at 24 weeks in patients treated with Vascugel compared to placebo.

Building on the successful results to date for Vascugel, Pervasis continues to apply its proprietary endothelial technology platform to develop additional therapies to treat vascular disease. Data for PVS-10200, a preclinical compound being developed to treat interventions performed for peripheral arterial disease (PAD), were published in the December issue of the Journal of Vascular and Interventional Radiology (Nugent et al. J Vasc Interv Radiol 2009; 20(12):1617-1624). In a preclinical model of PAD, administration of PVS-10200 at the time of angioplasty and stent placement enhanced blood vessel healing compared to angioplasty and stenting alone. Pervasis is now preparing to begin a Phase 1/2 study of PVS-10200 in the first half of 2010.

About Pervasis

Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts -- the failure of which result in serious complications and a significant increase in medical costs. The company's most advanced program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 trials in patients undergoing arteriovenous access procedures for hemodialysis. Pervas
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Doctors from the Sheikh Zayed ... National Health System are the first in ... osteoma, a benign but painful bone tumor that commonly ... magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. Two patients, ... Shah , have been treated successfully in a research ...
(Date:5/27/2015)... 2015 The report " Tube Packaging Market ... Oral Care, Food & beverages, Pharmaceuticals, Consumer Goods), by Material ... - Trends & Forecasts to 2020", published by MarketsandMarkets, The ... a CAGR of 6.65% from 2015, to reach $8,638.9 Million ... Tables and   61 F igures spread thro ...
(Date:5/27/2015)... , May 27, 2015  Vital Access Corp. announced ... credit facility with Deerfield Management, a healthcare investment firm. ... Vital Access, continued global expansion of its innovative VWING™ ... the Company,s proprietary vascular access platform. "Vital ... financial partner. Deerfield is a healthcare investor with great ...
Breaking Medicine Technology:Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4Tube Packaging Market Worth $8.63 Billion by 2020 2Tube Packaging Market Worth $8.63 Billion by 2020 3Tube Packaging Market Worth $8.63 Billion by 2020 4Vital Access Receives $10 Million Financing Commitment from Deerfield 2Vital Access Receives $10 Million Financing Commitment from Deerfield 3
(Date:5/27/2015)... Dr. Omar Ibrahimi, Dermatologist and Director ... has been selected as part of a controlled launch ... the only physician in Connecticut) to offer the new ... removal of submental fat (double chin). The procedure is ... surgery and minimal risks. Dr. Ibrahimi is an invited ...
(Date:5/27/2015)... 27, 2015 In support of a ... issue of the Journal of American Geriatrics Society about ... obesity, Bedford Commons OB-GYN P.A . is reiterating ... sweetener-flavored beverages. , To examine the relationship between ... San Antonio Longitudinal Study of Aging (SALSA) tracked the ...
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 – Memorial ... healthcare provider along the Gulf Coast to pioneer ... In partnership with MD Revolution, a digital care ... program that enables healthcare providers to easily meet ... new, user-friendly program is designed to improve patient ...
(Date:5/27/2015)... On June 5, Plan B [the agency ... LifeSource to host Donate Your Break, a public blood ... LifeSource donor coach outside of 116 W. Illinois (at ... for whole blood units is highest for LifeSource, the ... LifeSource requires approximately 1,000 donations per day to maintain ...
(Date:5/27/2015)... Meadows, IL (PRWEB) May 27, 2015 ... release of its SonarMD Platform, a first-of-its ... monitoring and managing patients with chronic gastrointestinal ... Kosinski, MD, MBA, the application allows physicians ... visits through the ongoing use of electronic ...
Breaking Medicine News(10 mins):Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... LAKE CITYFindings of a clinical trial reported at SNM,s ... agent could improve diagnosis of recurrent prostate cancer and ... "Despite definitive treatment, about 30 percent ... of the division of nuclear medicine and molecular imaging ...
... Public Health (HSPH) have found that children and adolescents ... smoke-free public places have significantly lower levels of a ... in counties with no smoke-free laws. The children ... laws had 39% lower prevalence of cotinine in their ...
... results from a major clinical trial show that ... women with advanced ovarian cancer and then continuing ... extends progression-free survival. Women receiving the new treatment ... 14.1 months, compared to 10.3 months for women ...
... June 5 The combination of two different chemotherapies ... cancers is not effective against advanced melanoma, according to ... 46th annual meeting of the American Society of Clinical ... we learn something important about the treatment of melanoma," ...
... and Tasigna than Gleevec , SATURDAY, June 5 (HealthDay ... (Tasigna), appear better than imatinib (Gleevec) in treating patients ... considered as first-line treatments, two new studies show. , ... be presented Saturday at the American Society of Clinical ...
... -- Two drugs approved for treatment of drug-resistant chronic ... a first therapy than the existing front-line medication, according ... England Journal of Medicine . Separate international ... year of treatment between the standard-of-care drug imatinib, also ...
Cached Medicine News:Health News:Molecular imaging detects recurrent prostate cancer 2Health News:Smoke-free air laws effective at protecting children from secondhand smoke 2Health News:New treatment regimen shown effective against advanced ovarian cancer 2Health News:Combination treatment regimen not effective against advanced melanoma 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 3Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 4Health News:Second-line CML drugs evoke faster, better front-line remissions 2Health News:Second-line CML drugs evoke faster, better front-line remissions 3
... The OcuLight family of infrared laser ... SLx models. These diode lasers serve as ... devices and applications, require no regular maintenance ... with their compact design. The OcuLight SLx ...
... mid range space saver specular microscope. It has ... the corneal endothelium automatically. It also has the ... central area. The image of the cells is ... with the system., This model is exactly the ...
... Danker Laboratories manufacturers ... RGP orthokeratology lenses (also ... or "Corneal Reshaping" Lenses) ... specifications and demanding standards ...
... The JSZ Orthokeratology (oprifocon A) ... permeable contact lenses used for ... corrects nearsightedness (myopia). The patient ... removes them in the morning. ...
Medicine Products: